Unravelling the Oncogenic Potential and Prognostic Significance of CKS1B in Human Lung Adenocarcinoma and Squamous Cell Carcinoma: A Comprehensive Computational Analysis

Lung cancer (LC) confers to radical malignancy with a limited recourse of therapy worldwide. Consequently, LC has become the leading cause of cancer deaths in both men and women globally. Non-small cell lung cancer (NSCLC), one of the major LC types and accountable for a greater share of these cancer-associated deaths, further branches out to adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC). A dearth of evident clinical symptoms coupled with the diagnosis feasibility only after advanced metastasis raises the need for precision in treatment apart from the existing chemical drug treatments. Precise guidance can be entailed by targeted therapies, utilizing the potential and thoroughly evaluated differentially expressed genes of cancer under speculation for tumor treatments. Cyclin-dependent kinase regulatory subunit 1B (CKS1B), a member of the conserved cyclin kinase subunit 1 (CKS1) protein family, regulates the cell cycle. Increasing evidence revealed that up-regulation of the CKS1B gene is associated with multiple human-related cancers, indicates its potential use as a targeted therapeutic for early detection and treatment. CKS1B has been found to be associated with poor prognosis in both LUAD and LUSC, while the prognostic significance of CKS1B in other types of cancer is not well established. Herein, we have performed a comprehensive bioinformatics analysis of factors involved in LUAD and LUSC with CKS1B and discussed its role as a potential biomarker for early lung cancer detection and treatment. While these evaluations demonstrate the immunotherapeutic features and prognostic value of CKS1B, further in vivo and in vitro studies are required to determine the accuracy of final applications.